Long-term response with sunitinib for metastatic renal cell carcinoma Journal Article

  


Authors: Ronnen, E. A.; Kondagunta, G. V.; Ginsberg, M. S.; Russo, P.; Motzer, R. J.
Article Title: Long-term response with sunitinib for metastatic renal cell carcinoma
Abstract: A 65-year-old man with metastatic renal cell carcinoma developed progressive disease after treatment with interferon-α. He began treatment with sunitinib, a multitargeted tyrosine kinase inhibitor, on clinical trial. The patient achieved a partial response after two cycles of therapy, with a durable response continuing after 2 years of treatment. This case report illustrates the long-term response to sunitinib for patients with metastatic renal cell carcinoma. © 2006 Elsevier Inc. All rights reserved.
Keywords: cancer chemotherapy; aged; case report; sunitinib; diarrhea; drug dose reduction; antineoplastic agents; bone metastasis; alpha interferon; lymph node metastasis; computer assisted tomography; tumor volume; stomatitis; kidney carcinoma; kidney neoplasms; time factors; carcinoma, renal cell; drug response; remission induction; indoles; pyrroles; kidney metastasis; antidiarrheal agent; adrenal metastasis
Journal Title: Urology
Volume: 68
Issue: 3
ISSN: 0090-4295
Publisher: Elsevier Science, Inc.  
Date Published: 2006-09-01
Start Page: 672.e19
End Page: 672.e20
Language: English
DOI: 10.1016/j.urology.2006.03.042
PUBMED: 16979716
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-33749128978&partnerID=40&md5=85057cbdbaf53522fb8f8a082851048d
Notes: --- - "Cited By (since 1996): 4" - "Export Date: 4 June 2012" - "CODEN: URGYA" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Ellen Arielle Ronnen
    11 Ronnen
  2. Paul Russo
    581 Russo
  3. Gnanamba Kondagunta
    46 Kondagunta
  4. Robert Motzer
    1243 Motzer
  5. Michelle S Ginsberg
    235 Ginsberg
Related MSK Work